NEW Podcast #GLP-1s, Weight and #Exercise in #MS Impact on inflammation & neuroplasticity! Dr. Stuve @UTSWMedCenter & Trevor @MSGym1 bit.ly/4zNjTiT🍏apple.co/4iFQH7i @narologist @jsabatino37 @C_OrejaGuevara @anneke_vdw #NeuroTwitter Sponsor: @TGTherapeutics

Oh: Phase 3 fenebrutinib reduced slowly expanding lesion (SEL) counts by 21.5% vs ocrelizumab in PPMS and 18.3% vs teriflunomide in RMS. SEL volumes reduced 27.5% and 30.5%, respectively. Fewer patients on fenebrutinib accumulated PRLs. #MSTORONTO2026

Eshaghi: AI can be used in reading MRI scans for #MS including cerebral lesions, brain volumetrics, cord atrophy and cord lesions. Future development may redefine prognostic capability. #MSTORONTO2026

Alping: Risk of inflammatory bowel disease on rituximab increased. 62% of IBD events were classified as Crohn's disease. Number Needed to Harm: 131 patients over 5 years. #MSTORONTO2026

Varjú: Danish #MS registry shows a dramatic shift in switch from escalation strategy to early use of high efficacy treatment. No difference in PIRA outcomes between these approaches. 🤔 Controlling for all variables seems challenging…. #MSTORONTO2026

Checkout my @ECTRIMS poster. ENHANCE study: #MS patients switching from ocrelizumab to #ublituximab had 69% reduction in wearing-off at week 24. Patients with B cells despite ocrelizumab became depleted on ublituximab. 👉bit.ly/4iycUUh #MSTORONTO2026

Sormani: Pooled FENhance 1 and 2 RMS. Fenebrutinib compared to teriflunomide ⬇️relapses 55%, ⬇️ enhancing lesions 75% and ⬇️ new/enlarging T2 80%. Composite disability results below. #MSTORONTO2026

Excited to arrive at @ECTRIMS in Toronto to share and learn about the latest developments in multiple sclerosis. Looking forward to real progress for people living with #MS globally. 🌎Updates to follow! #MSTORONTO2026

Sleep fixes sleepiness. It doesn't always fix MS fatigue. New MS Living Well Pod 🎧: @RonaMossMorris @KingsCollegeLon shares what really works. bit.ly/4yXOeKG 🍎apple.co/4yB40KP #MSToronto2026 @KlausSchmierer @C_OrejaGuevara @DocforMS Sponsor: @TGTherapeutics

Sleep fixes sleepiness. It doesn't always fix MS fatigue. New #MSLivingWell Pod 🎧 @brainboyneuro1 talks @RonaMossMorris about what actually helps you get your energy back! bit.ly/4yXOeKG 🍎apple.co/4yB40KP @Brandon_Beaber @themsguide @MSViewsandNews @MarkWebb_

Worried your MS therapy raises your cancer risk? The long-term data may surprise you. New #MSLivingWell episode🎧Drs. Esther Melamed & Melinda Magyari; Host @brainboyneuro1 bit.ly/3TdjnKM 🍏apple.co/46HoeXF @MStranslate @MustStopMS @themsguide @MarkWebb_

Worried your MS therapy raises your cancer risk? The long-term data may surprise you. New #MSLivingWell episode🎧Drs. Esther Melamed & Melinda Magyari; Host @brainboyneuro1 bit.ly/3TdjnKM 🍏apple.co/46HoeXF @Brandon_Beaber @MSViewsandNews Sponsor: @TGTherapeutics

Can targeted exercise rewire the brain to improve function in #MS? Trevor Wicken @TheMSGym1 shares strategies on New MS Living Podcast. bit.ly/4zNjTiT🍏apple.co/4iFQH7i @MustStopMS @eurims @DrJNicholas @MarkWebb_

Could #GLP1 meds like Ozempic/Mounjaro do more for people with #MS than weight loss? Reduce inflammation, neuroprotection & myelin repair? New Podcast🎧 Guest: Dr. Stuve @UTSWMedCenter bit.ly/4zNjTiT🍏apple.co/4iFQH7i @Brandon_Beaber @MSViewsandNews @MStranslate

👏Phase 3 REMODEL #remibrutinib relapsing #MS: Superior⬇️ annualized relapse rate (ARR) & inflammatory brain lesions vs. teriflunomide. Positive trend in 3-month confirmed disability progression. Favorable safety profile with no liver safety signal. #BTKi bit.ly/4h6Douv

#CAREGIVING for someone with #MS? 🎧 Listen in to this new episode on MS Living Well podcast with @KennethPakenham, Dan Shaul & @brainboyneuro1 bit.ly/4pBqrg2 🍏apple.co/4fNsRoc @KlausSchmierer @C_OrejaGuevara @anneke_vdw @bart_professor Sponsor: @TGTherapeutics